-+ 0.00%
-+ 0.00%
-+ 0.00%

VolitionRx Q2 FY26 operating loss narrows 34% to $4.2 million; operating expenses fall 32% on year

PUBT·08/13/2026 20:19:31
Listen to the news
VolitionRx Q2 FY26 operating loss narrows 34% to $4.2 million; operating expenses fall 32% on year
  • VolitionRx Q2 2026 revenue was USD 0.4 million, roughly flat versus the year-earlier quarter.
  • Operating loss narrowed 34% to USD 4.2 million; operating expenses fell 32% on a cost-reduction program.
  • Net cash used in operating activities decreased 18% to USD 5.2 million.
  • First-half 2026 revenue more than doubled to USD 1.4 million, up 112% from the prior-year period.
  • Management cited talks with over a dozen diagnostics groups on licensing; highlighted Sysmex collaboration and a potential USD 5 million feline milestone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608131610PR_NEWS_USPR_____LN25869) on August 13, 2026, and is solely responsible for the information contained therein.